

PART I	Particulars	Standalone				Standalone	
		Quarter ended		9 months ended		9 months ended	
		December 31, 2013 (unaudited)	September 30, 2013 (Unaudited)	December 31, 2012 (unaudited)	December 31, 2013 (unaudited)	December 31, 2012 (unaudited)	March 31, 2013 (Audited)
1	a) Income from Operations b) Other Operating income Net Income from Operations	2,669.48 10.21 2,679.69	2,806.04 11.40 2,817.44	2,568.91 15.66 2,604.57	8,687.85 29.05 8,696.90	7,292.96 113.73 7,406.69	9,682.81 152.30 9,835.11
2	a) Drugs and Consumables b) Employees Cost c) Professional Charges-Doctors d) Clinical Establishment Fee e) Net Depreciation and amortization f) Other Expenditure Total Expenditure	555.89 348.16 656.19 414.66 49.07 503.34 2,528.41	630.12 370.71 646.20 428.02 51.41 515.86 2,648.32	577.77 320.63 611.09 333.86 147.22 458.48 2,352.06	1,766.28 1,070.62 1,940.27 1,249.70 147.22 1,660.88 7,668.35	1,538.88 1,002.50 1,847.63 333.86 203.27 1,660.88 6,588.02	2,025.60 1,326.60 2,467.58 730.57 249.04 2,087.16 8,886.55
3	Profit from operations before other income, interest & exceptional items (1-2)	151.28	171.12	252.51	428.55	818.67	958.56
4	Other Income	167.58	165.26	129.18	492.28	278.20	278.20
5	Profit before Interest & Exceptional Items (3 + 4)	318.86	336.38	381.69	920.83	947.72	1,236.76
6	Finance Cost	13.06	14.25	17.07	35.75	72.14	80.04
7	Profit from ordinary activities after Finance cost but before Exceptional items and Tax (5 - 6)	305.80	322.13	364.62	885.08	875.58	1,156.72
8	Exceptional items - Interest income (Refer Note 3 below)	-	322.13	27.39	-	353.28	353.28
9	Profit from Ordinary Activities before Tax (7 + 8)	305.80	644.26	392.01	885.08	1,228.86	1,510.00
10	Tax expense	104.06	116.77	127.18	308.07	398.70	492.58
11	Net Profit from Ordinary Activities after Tax	201.74	205.36	264.83	577.01	830.16	1,017.42
12	Profit on Sale of Clinical Establishment Business (Net of Tax Exp) (Refer Note 4 below)	-	-	3,337.57	-	3,337.57	3,300.54
13	Net Profit after tax	201.74	205.36	3,602.40	577.01	4,167.73	4,317.96
14	Paid up Equity Share Capital (Face Value Rs. 10 each)	1,860.95	1,860.95	1,860.95	1,860.95	1,860.95	1,860.95
15	Reserves excluding Revaluation Reserves	-	-	-	-	-	5,814.97
16	Earnings Per Share (EPS) - Basic (Rs.) - Before Extraordinary items - After Extraordinary items	1.08 1.08	1.10 1.10	1.42 1.42	3.10 3.10	4.46 4.46	5.47 5.46
17	Earnings Per Share (EPS) - Diluted (Rs.) - Before Extraordinary items - After Extraordinary items	1.08 1.08	1.10 1.10	1.42 1.42	3.10 3.10	4.46 4.46	5.46 5.46

PART II	Particulars	[Not Annualised]		[Not Annualised]		[Not Annualised]	
		December 31, 2013 (unaudited)	September 30, 2013 (Unaudited)	December 31, 2012 (unaudited)	December 31, 2013 (unaudited)	December 31, 2012 (unaudited)	March 31, 2013 (Audited)
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding	6,841,857	6,841,857	6,841,857	6,841,857	6,841,857	6,841,857
	- Number of Shares	36.80%	36.80%	36.80%	36.80%	36.80%	36.80%
	- Percentage of shareholding						
2	Promoters and promoters group Shareholding						
	a) Pledged / Encumbered						
	- No. of shares						
	- % of shares (as a % of total shareholding of promoter and promoter group)						
	- % of shares (as a % of total share capital of the company)						
	b) Non-Encumbered						
	- No. of shares	11,752,402	11,752,402	11,752,402	11,752,402	11,752,402	11,752,402
	- % of shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- % of shares (as a % of total share capital of the company)	63.20%	63.20%	63.20%	63.20%	63.20%	63.20%

B	Particulars	Quarter ended 31-12-2013	
		December 31, 2013 (unaudited)	September 30, 2013 (Unaudited)
	Pending at the beginning of the quarter		
	Received during the quarter	23	23
	Disposed off during the quarter		
	Remaining unresolved at the end of the quarter		

Notes

- The above unaudited financial results have been reviewed by the Audit, Risk and Controls Committee, approved and taken on record by the Board of Directors in their meeting held on January 24, 2014.
- The Company operates in one reportable segment i.e., Multi speciality Hospital Services in terms of Accounting Standard 17.
- Interest income aggregating Rs 27.39 Lakhs relating to quarter ended December 31, 2012 (year ended December 31, 2012 - Rs 353.28 lakhs), earned on inter corporate Deposits placed out of advance money received from Fortis Health Management Limited (FHML) towards sale of 'Clinical establishment business' (CEB) upto October 16, 2012, being the effective date of transfer of the CEB has been disclosed as an exceptional item and the related interest income pertaining to the period subsequent to October 16, 2012 has been included as part of other income.
- During quarter ended December 31, 2012, the Company had completed the sale of its 'Clinical establishment business' to Fortis Health Management Limited (FHML) (collectively, 'the parties') pursuant to the business transfer agreement (BTA), dated August 27, 2012. Accordingly, the net assets of Rs. 2,308.93 Lakhs of the clinical establishment business have been transferred as a going concern on a slump sale basis effective October 17, 2012 for an aggregate consideration of Rs 7,000 lakhs. The net profit aggregating Rs 3,300.54 Lakhs (net profit aggregating Rs. 839.51 Lakhs arising from the sale of the said business has been disclosed as an "extraordinary item".
- Previous period figures have been regrouped, wherever considered necessary, to conform to current period presentation.



By Order of the Board
 For and on Behalf of Board of Directors
 V. Vijayarathna V
 Whole Time Director


Limited Review Report**Review Report to
The Board of Directors
Fortis Malar Hospitals Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Fortis Malar Hospitals Limited ('the Company') for the quarter ended December 31, 2013 ("the Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding', which have been traced from disclosures made by the management and have not been reviewed by us. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25, Interim Financial Reporting (notified under the Companies Act, 1956 read with General Circular 15/2013 dated 13 September 2013, issued by the Ministry of Corporate Affairs, in respect of Section 133 of the Companies Act, 2013) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S. R. Batliboi & Co. LLP

Chartered Accountants

ICAI Firm registration number: 301003E

**per Aniruddh Sankaran**

Partner

Membership No.: 211107

Place: Chennai

Date: January 24, 2014



FORTIS MALAR REPORTS 3% REVENUE GROWTH AT RS 26.80 CR, for Q3FY14
OPERATING EBITDA AT RS 2.00 CR
NET PROFIT AT RS 2.02 CR

Chennai, January 24, 2013: Fortis Malar Hospitals Ltd., a subsidiary of Fortis Healthcare Ltd., today announced its unaudited financial results for the quarter ended December 31, 2013.

Financial Highlights for the Quarter (Q3FY2014)

- Fortis Malar Hospitals recorded an Operating revenue of Rs 26.80 Cr., a growth of 3% over the corresponding quarter of the previous year.
- Operating Profit (EBITDA) for the period stood at Rs.2.00 Cr against Rs. 3.03 Cr reported during the same period last year. The decline in EBITDA is due to impact of clinical establishment fee for the full quarter in Q3FY14 compared to partial impact during Q3FY13 (Clinical establishment fees starting from 20th October 2012)
- Profit from ordinary activities before exceptional, extraordinary items and tax was at Rs. 3.06 Cr as compared with Rs. 3.65 Cr reported during the corresponding quarter of the previous year.
- Net profit for the quarter from ordinary activities was at Rs.2.02 Cr against Rs.2.65 Cr reported during the same period last fiscal.
- Net profit after tax for the quarter stood at Rs.2.02 Cr.

Operational Highlights for the quarter

- The Cardiologists team at Fortis Malar successfully performed two Heart transplants during the quarter.
- During the quarter, 15 renal transplants were performed at the hospital compared to 10 transplants done during the same period last year.
- A patient with heart and kidney failure who was breathless at rest and on regular dialysis underwent a successful surgical procedure wherein his Hernia repair was performed under Electro acupuncture with local anesthesia.

- A young patient with polytrauma successfully underwent an emergency Craniotomy and Tibial Nailing at Fortis Hospital, during the quarter.
- A patient with seizure disorder who was undergoing de-addiction therapy sustained multiple spine fractures and was referred from the de-addiction centre. He successfully underwent multilevel Minimally Invasive Spine Stabilisation.
- A team of Doctors successfully performed Sleeve Gastrectomy (Bariatric) surgery on a patient with BMI of 42, hypothyroidism and hypertension.
- A young lady with severe anemia, hypertension and ectodermal dysplasia underwent a surgery wherein doctors performed Radical Nephrectomy for a large tumor infiltrating into her pancreas.

Corporate Social Responsibility

Playing its part as a good social corporate citizen, Fortis Malar has been involved in activities that contribute to society. The following CSR activities were undertaken during the quarter:

- As part of the Fortis Heart Saver initiative, Free Cardio Pulmonary Resuscitation (CPR) training programs were conducted on various dates for the general public benefitting more than 500 people, so far.
- Health awareness programs were conducted on the occasion of World Arthritis day, World Spine day, World stroke day, Anti obesity week, World diabetes day, National Epilepsy day.
- Joy of giving Week (2-8th Oct) – On this occasion we collaborated with an NGO and organized an event “Triumph of Hearts” and the event was attended by large gathering.
- Various Cardiac, Ortho, Dental and Vaccination camps conducted at various corporate and Government organizations.
- Health awareness talks and workshops were organized at various Corporates and Government organizations.

Commenting on the results Mr Aditya Vij, Chairman, Fortis Malar Hospitals Limited, said,

“The current quarter witnessed a muted growth in revenues compared to same time last year after record revenues in Q2 2013. The Company continues to be a destination for high end and complex procedures as witnessed by numerous rare procedures done in your hospital. ”

About Fortis Malar Hospitals Ltd

Fortis Malar Hospital (formerly known as Malar Hospital) was acquired by Fortis Healthcare (India) Limited in early 2008. The hospital founded in 1992, is established as one of the largest corporate hospitals in Chennai providing quality super specialty and multi specialty healthcare services. Fortis Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynaecology, Orthopaedics, Gastroenterology, Neurology, Paediatrics, Diabetics, Nephrology and Internal Medicine.

Fortis Malar Hospital has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Paediatric Cardiac surgeries, Orthopedic and Joint replacements, Neurosurgeries and Plastic reconstruction surgeries have been performed at this hospital. The hospital's Obstetrics and Gynaecology services are among the busiest in the city, successfully performing many complicated deliveries and surgeries. They are supported by a dedicated Neonatology unit.

About Fortis Healthcare Ltd

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty. Currently, the company operates its healthcare delivery services in India, Singapore, Dubai, Mauritius and Sri Lanka with 65 healthcare facilities (including projects under development), over 10,000 potential beds, over 240 diagnostic centres and a team strength of more than 17,000 people.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

FOR MORE INFORMATION PLEASE CONTACT

Priyam Bortamuli
Fortis Malar Hospitals Ltd
Mobile : 9845558559
Priyam.Bortamuli@fortishealthcare.com

Sumit Jain
K2 Communications Pvt Ltd
Mobile: 9886021715
Sumit.jain@k2communications.in